At present, percutaneous coronary intervention (PCI) is the most common coronary revascularization strategy. One of its benefits is that patients can be safely discharged when procedures are programed, which helps decompress hospital capacity. However, this strategy has not been validated for acute coronary syndromes; the evidence gathered for non-ST elevation ACS is far from robust,<a href="https://solaci.org/en/2022/07/11/same-day-discharge-in-nste-acs-is-it-possible/" title="Read more" >...</a>
Is IVUS Guided PCI a Common Technique?
We all know the benefits of ultravascular ultrasound (IVUS) in the development of percutaneous coronary intervention, such as more accurate vessel measurement, improved stent expansion and apposition, and complication identification. This is why the use of IVUS is a class IIa recommendation in AHA and ESC guidelines. The aim of this retrospective study was to<a href="https://solaci.org/en/2022/07/06/is-ivus-guided-pci-a-common-technique/" title="Read more" >...</a>
An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty
The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet therapy (DAPT) in 4579 patients treated with angioplasty and a biodegradable polymer sirolimus-eluting stent. This recent publication on the same study analyzed the evolution within the same strategies of the subgroup of patients with complex angioplasty and compared<a href="https://solaci.org/en/2022/07/06/an-abbreviated-dual-antiplatelet-regimen-is-also-safe-in-patients-at-high-risk-for-bleeding-undergoing-complex-angioplasty/" title="Read more" >...</a>
High Risk of Bleeding after PCI: More Evidence for Short DAPT
Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy after DES stenting to reduce ischemic events. However, in patients with elevated risk of bleeding (HBR) guideline and expert recommendations is 1-6 months, since there is plenty of evidence in favor, except for a randomized study, the MASTER<a href="https://solaci.org/en/2022/07/06/high-risk-of-bleeding-after-pci-more-evidence-for-short-dapt/" title="Read more" >...</a>
IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory
Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized studies have shown their effectiveness and benefit in femoropopliteal territory, and even though the use of paclitaxel coated balloons has been called into question, a retrospective study including 168,553 patients was able to show paclitaxel coated balloons were<a href="https://solaci.org/en/2022/06/27/in-pact-global-follow-up-of-real-life-patient-in-femoropopliteal-territory/" title="Read more" >...</a>
Takotsubo Syndrome: Does Gender Impact Prognosis?
Takotsubo Syndrome (STT) is characterized by acute cardiac failure which can be reversed in many occasions, but is associated with morbidity and mortality at short and long term. It is most frequent among women, especially after menopause. However, gender differences have not been looked into when analyzing the evolution of this cardiomyopathy. This was an<a href="https://solaci.org/en/2022/06/22/takotsubo-syndrome-does-gender-impact-prognosis/" title="Read more" >...</a>
PCI on Native Arteries or Saphenous Vein Grafts: Which Has Better Prognosis?
New revascularization after coronary artery bypass graft (CABG) is often needed, be it because of severe bridge lesion, intimal hyperplasia, thrombosis, atherosclerosis, or native vessel lesion progression. We therefore need to determine the best revascularization strategy, namely native or graft percutaneous intervention, venous or arterial, or repeat surgery, with the risk it entails. There is<a href="https://solaci.org/en/2022/06/21/pci-on-native-arteries-or-saphenous-vein-grafts-which-has-better-prognosis/" title="Read more" >...</a>
The Current Role of Thrombus Aspiration in Primary PCI
In general, thrombus aspiration in acute myocardial infarction (AMI) has not been shown beneficial by large studies. It could even be prejudicial, since it has been associated with stroke. However, there are certain scenarios where the presence of a significant number of these prevents us from reaching adequate TIMI flow 3, or is associated with<a href="https://solaci.org/en/2022/06/15/the-current-role-of-thrombus-aspiration-in-primary-pci/" title="Read more" >...</a>
Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results
Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel. Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons. The aim of this randomized, multicenter study was to evaluate<a href="https://solaci.org/en/2022/06/13/using-biolimus-coated-balloons-for-treating-small-vessel-disease-yields-promising-results/" title="Read more" >...</a>
TAVR, More Information Supports Its Use
TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>